Search for content, post, videos

Category

Legal Advice

0 COMMENT
41 Views
Asset Value

For life science companies, putting a price on their most valuable resources – ideas, research, proposals and prototypes – can be difficult. Yet the need to protect these assets is critical to preserving a company’s overall value and its ability to move any research forward. Since intellectual property often is…

lars-hedbys
0 COMMENT
34 Views
Idogen’s technology granted European patent

Idogen announces that the European Patent Office will formally grant a patent application, covering the company’s tolerogenic vaccine technology. The EPO approval strengthens the company’s patent portfolio for the vaccine technology. A patent in the same patent family has already been granted in Japan and a Notice of Allowance has…

peter_z_index_pharma
0 COMMENT
7 Views
InDex Pharmaceuticals granted patent in the US

InDex Pharmaceuticals Holding announces that a patent covering 19 compounds from the company’s DIMS platform has been granted by the United States Patent and Trademark Office (USPTO). InDex has a discovery stage portfolio of more than 150 DNA-based ImmunoModulatory Sequences (DIMS), several of which are already protected by approved composition-of-matter…

idogen
0 COMMENT
10 Views
Idogen strengthens its position in the US

Idogen announces that the United States Patent & Trademark Office has issued a “Notice of Allowance”, which means that it intends to grant Idogen’s patent application. The United States Patent & Trademark Office (USPTO) has communicated its intention to grant Idogen’s Patent Application No. 14/553,098. The patent belongs to Idogen’s…

lars-hedbys-idogen
0 COMMENT
2 Views
Idogen reaches formal granting of patent in Japan

Idogen has announced that the Japan Patent Office (“JPO”) has granted the company’s patent application. The patent provides Idogen’s vaccine technology with a broad protection and further strengthens the company’s patent portfolio in an important market. The Japan Patent Office has now formally granted Idogen’s Patent Application covering induction of…

aldgate-tower
0 COMMENT
2 Views
EU patent court to open in December

The new Europe’s Unified Patent Court, partly based in London, is expected to open in December this year. The UPC Preparatory Committee has said that it is working ‘under the assumption’ that the court will become operational before the end of year – with a targeted opening date of 1…

orexo nikolaj sorensen
0 COMMENT
2 Views
Orexo appeal Zubsolv US district court decision

Orexo has appealed the decision rendered by the United States District Court for the District of Delaware on November 15, 2016 regarding the validity of Orexo’s US Patent No. 8,940,330 protecting Zubsolv. The decision was rendered in the patent litigation regarding Actavis’s generic Zubsolv 1.4/0.36 mg and 5.7/1.4 mg buprenorphine/naloxone…

marketing-rules
0 COMMENT
1 Views
Marketing Regulations

While pharmaceutical companies in Sweden and the United Kingdom claim to police their own marketing practices, when it comes to promoting products, a long list of violations tells a different story, according to a recent study by three researchers from the University of Lund, Sweden. The researchers, Anna V. Zetterqvist,…

targovax board of directors
0 COMMENT
2 Views
Targovax granted European Patent for ONCOS-102

Targovax announces the grant of European Patent no 2,379,586. This composition of matter patent protects Targovax’s lead product from its ONCOS platform, the oncolytic viral product ONCOS-102 and expires in 2029. A US patent covering ONCOS-102 was granted in May 2016. Targovax’s proprietary ONCOS platform generates novel oncolytic viruses, an…